MG-132

For research use only.

Catalog No.S2619

1138 publications

MG-132 Chemical Structure

Molecular Weight(MW): 475.62

MG132 is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 μM and 1.2 μM for the inhibition of proteasome and calpain, respectively. MG132 activates autophagy and induces apoptosis in tumor cells.

Size Price Stock Quantity  
USD 50 In stock
USD 170 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's MG-132 had a noticeably greater effect when compared with similar products from Sigma: This is directly due to using the (S, R, S) - (-) - 2 configuration.

P21 protein can be degraded through ubiquitylation pathway. Inhibition of proteasome activities results in the accumulation of P21 protein, therefore, the more powerful the inhibiting effect, the more P21 protein is accumulated. (testing protein: P21; Cell line: Hela; treatment condition: final concentration of MG-132 is 5μM, with a 6 hour treatment time)

Selleck's MG-132 has been cited by 1138 publications

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Biological Activity

Description MG132 is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 μM and 1.2 μM for the inhibition of proteasome and calpain, respectively. MG132 activates autophagy and induces apoptosis in tumor cells.
Targets
Proteasome [9]
(Cell-free assay)
100 nM
In vitro

MG-132 displays >1000 times more activity than ZLLal in inhibiting the ZLLL-MCA-degrading activity of 20S proteasome with IC50 of 100 nM versus 110 μM. MG-132 also inhibits calpain with IC50 of 1.2 μM. MG-132 induces neurite outgrowth in PC12 cells at an optimal concentration of 20 nM, displaying 500 times more potency than ZLLal. [1] MG-132 (10 μM) potently inhibits TNF-α-induced NF-κB activation, interleukin-8 (IL-8) gene transcription, and IL-8 protein release in A549 cells by inhibition of proteasome-mediated IκBα degradation. [2] MG-132 treatment potently induces p53-dependent apoptosis in KIM-2 cells by 26S proteasome inhibition. [3] Unlike BzLLLCOCHO or PS-341, MG-132 treatment results in weak inhibition of the chymotrypsinlike (CT-L) and peptidylglutamyl peptide hydrolysing (PGPH) activities of the 26S proteasome, whereas multiple myeloma cells (U266 and OPM-2) are more sensitive to induction of apoptosis by MG-132 than BzLLLCOCHO. [4] MG-132 (1 μM) sensitizes TRAIL-resistant prostate cancer cells by activating the AP-1 family members c-Fos and c-Jun, which, in turn, repress the antiapoptotic molecule c-FLIP(L). [5] MG-132 significantly enhances the ability of inositol hexakisphosphate (IP6) to reduce cellular metabolic activity in both PC3 and DU145 androgen-independent prostate cancer (AIPCa) cell lines. [6]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
LPS-stimulated RAW264.7 cells NYHDWJZsTnWwY4Tpc44hSXO|YYm= M1i1[FI2KM7:TR?= NGXQ[2JFVVOR NX72fFVoUW6qaXLpeJMhdmm2cnnjJI95cWSnIIDyc4R2[3Srb36ge4l1cCCLQ{WwJI9nKDBwMTFOwG0> MoTtNlQ3QTd2OU[=
HL-60 NEf2SVhEgXSxdH;4bYMhSXO|YYm= M1fmflQxKM7:TR?= MXm0PEBp NXfxfo9JTE2VTx?= MlS2TWM2ODxzMDFOwG0> M{m0WVI1Pjl5NEm2
SMMC-7721 MoDNR5l1d3SxeHnjJGF{e2G7 M{K0bFQxKM7:TR?= NYf5VmpsPDhiaB?= MUfEUXNQ NVm4TVNSUUN3ME23MlEh|ryP Ml7YNlQ3QTd2OU[=
A-549 MWHDfZRwfG:6aXOgRZN{[Xl? NF20Zlc1OCEQvF2= MoW5OFghcA>? Mk\uSG1UVw>? MkPYTWM2ODxzMDFOwG0> M4PNSFI1Pjl5NEm2
MCF-7 MmnWR5l1d3SxeHnjJGF{e2G7 NWjuU2NTPDBizszN M2rTRVQ5KGh? MnrFSG1UVw>? Mm\tTWM2OD15LkOg{txO NYT3TXpVOjR4OUe0PVY>
SW-480 MYfDfZRwfG:6aXOgRZN{[Xl? MXi0NEDPxE1? NHnVSmM1QCCq NF3YT5FFVVOR NILQfW9KSzVyPUSg{txO NHTnNlEzPDZ7N{S5Oi=>
NCI-H929 MWXDfZRwfG:6aXOgRZN{[Xl? Mn\tNUDPxE1? NF7aSW84OiCq NV[4eWpkTE2VTx?= MVvJR|UxRTBwMUeg{txO NXHCNmU3OjR4MkWwPFg>
293T M3vVSmN6fG:2b4jpZ{BCe3OjeR?= MYKxNEDPxE1? NEnw[5A4OiCq NF;NN3RFVVOR MULJR|UxRDJizszN M3WzflI1PjJ3MEi4
293T MkPTSpVv[3Srb36gRZN{[Xl? NXr1TWlMOTBizszN NYTrV2RKOjRiaB?= M3\LTGROW09? MXHNc4RmemG2ZXz5JIlv\HWlZYOgbIVifC2|aH;jb{Ah MViyOFYzPTB6OB?=
HeLa MVPLbY5ie2ViQYPzZZk> M1HZbVExKM7:TR?= NXTOOmI2OSCq NUi3ZXFwTE2VTx?= NEOwXHpKdmS3Y3XzJHBCWlBiY3zlZZZi\2ViYomgbY5pcWKrdHnu[{Bxem:|ZXHzc41mKGGldHn2bZR6 MVyyOFMzOTh|Mx?=
MDA-MB-231 M131Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;XNUDPxE1? MXO3NkBp M2r3[WROW09? NHTxbIVKSzVyPUCuNVgh|ryP NF;QepgzPDF3M{KwOi=>
MCF-7 NITXcVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYKxJO69VQ>? MofRO|IhcA>? MWfEUXNQ MlTvTWM2OD1yLkGzJO69VQ>? MYiyOFE2OzJyNh?=
MCF10A MkHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnlPYZUOSEQvF2= MlnMO|IhcA>? MVzEUXNQ M3i3WGlEPTB;MD6yPUDPxE1? NHH3bpczPDF3M{KwOi=>
HEK-293 NVn0R3ByU2mwYYPlJGF{e2G7 MoL1NkBidmRiMkCg{txO M2TU[FIhcA>? NEnZd41FVVOR MkizTY5pcWKrdIOgR4hVNUxiYXP0bZZqfHlid3n0bEBKSzVyIH;mJFkhdk1i MVWyN|U1ODd7MB?=
Calu6 M4j4XWZ2dmO2aX;uJGF{e2G7 M2TMVVExKM7:TR?= NXzMNmFwOThiaB?= MWnEUXNQ MoXnV4lodmmoaXPhcpRtgSCjY3P1cZVt[XSnczDmdoF1[XirbjDwdoVkfXK|b4K= NFGz[|IzOzVyNkS4Oi=>
IFN-gamma-induced RAW264.7 MlXGSpVv[3Srb36gRZN{[Xl? MkHPSG1UVw>? Mn3GTY5pcWKrdIOgcol1emmlIH;4bYRmKHC{b3T1Z5Rqd25id3n0bEBKSzVyIH;mJFAvODd5IN88US=> MnTQNlIzPzd{N{e=
IPC227F NGq2OGJEgXSxdH;4bYMhSXO|YYm= NFe0c3oyKM7:TR?= NYrzPZJKPDhiaB?= MmD1SG1UVw>? NIKyS4RKSzVyPUCuNFc4KM7:TR?= NInWemUzOTl{NEWyPC=>
Hepa-1c1c7 NIXQdYxHfW6ldHnvckBCe3OjeR?= Mn;ENlUh|ryP M1vXdFYhcA>? MWrEUXNQ NEP0Z2hKdmO{ZXHz[ZMhVnKoMjDwdo91\WmwIHzleoVt MUKyNFM6OjV2NB?=
COS-7 MkfnR5l1d3SxeHnjJGF{e2G7 NVOzVm5xOTBizszN NUjXWXBUTE2VTx?= NV3yUFB[UUN3MEyxNEDPxE1? M1u4XFE5ODh6MEm3
HuH-7 M2T5fGN6fG:2b4jpZ{BCe3OjeR?= NUTYWYRVOTBizszN MkPTSG1UVw>? NYLvO29uUUN3MEyxNEDPxE1? MVWxPFA5QDB7Nx?=
OCI-Ly3 NUTM[m4yTnWwY4Tpc44hSXO|YYm= MoHkNVAh|ryPwrC= NV3S[G9xPCCq NHPuZmRFVVOR M2ns[Glv\HWlZYOgbJVu[W5iSXvhdJBiSmGucHjhJJN1[WKrbHn6ZZRqd25id3n0bEBGSzVyIH;mJFEh|ryP NVfjTJJkOThyMkSxNVM>
A2780 cDDP MYXBdI9xfG:|aYOgRZN{[Xl? MYmyOEBp NXjuN5c3TE2VTx?= MlzVTY5lfWOnczDhdI9xfG:|aYOgZpkhcW6qaXLpeIlv\yCSVFXOJIRm\3KjZHH0bY9v NUfze5d6OTd4OESwNVg>
LPS-stimulated RAW264.7 cells NHLzXmNHfW6ldHnvckBCe3OjeR?= NITw[nJFVVOR NY\rT3NuUW6qaXLpeJMhVkZva3HwdIFDKESQQTDibY5lcW6p M4PsZ|E4PDB5Mke3
PC12 NFz4U3JHfW6ldHnvckBCe3OjeR?= M1i5[lExOCEQvF5CpC=> MYSyOEBp MnLOSG1UVw>? NFHYSlZKdmirYnn0d{A3NU:KRFGtJIFv\CCKMl:yMYlv\HWlZXSgZ5l1d3SxeHnjbZR6 MnS0NVcyPTh2NUS=
PC3 NWrKRWRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWOyNEDPxE1? NGC5Z4g1QCCq NWjLN4w6TE2VTx?= MXHJR|UxRTBwNjFOwG0> M1PDUFE3Pjh4NUO3
LP-1 NXfMXWJPSXCxcITvd4l{KEG|c3H5 NVu2[Yx5OzByIH7N MmH3NlQhcA>? MnTsSG1UVw>? MkP0TY5lfWOnczDhdI9xfG:|aYOgZpkhcW6lcnXhd4lv\yClbHXheoVlKFCDUmCgcIV3\WxiYX7kJJJm\HWlaX7nJG1kdC1zIIDyc5RmcW5ibHX2[Yw> MWSxOVk2QDV6OR?=
ES6 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYG3c4ZGUUN3ME2wMlAyOzB4IN88US=> MWXTRW5ITVJ?
A101D NFW0bJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7OTWM2OD1yLkCzNlc6KM7:TR?= MYPTRW5ITVJ?
OCUB-M NFrPOYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTBwMEO3N|ch|ryP NEntOXRUSU6JRWK=
LB2518-MEL M3XKR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLnR4JKSzVyPUCuNFM4PiEQvF2= MVPTRW5ITVJ?
SH-4 M{\Jcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITVS5JKSzVyPUCuNFQ{OSEQvF2= NGnIdGpUSU6JRWK=
KNS-42 NUX5PYd6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETY[GtKSzVyPUCuNFQ1PDFizszN NUH5Rll3W0GQR1XS
DSH1 M4noZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfzempKSzVyPUCuNFUzQDlizszN M1LNdXNCVkeHUh?=
NTERA-S-cl-D1 M1[0RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PsU2lEPTB;MD6wOVc4OiEQvF2= MV\TRW5ITVJ?
D-542MG MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TMZmlEPTB;MD6wOVk2PyEQvF2= MkjHV2FPT0WU
KS-1 NXu0PY9GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33CW2lEPTB;MD6wOlQ2QCEQvF2= NH3OfmdUSU6JRWK=
BL-41 Mn2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2j6N2lEPTB;MD6wOlk1PyEQvF2= NEm5c2FUSU6JRWK=
LXF-289 NHTO[29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4e1bWlEPTB;MD6wO|A3PiEQvF2= MlPjV2FPT0WU
D-247MG MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjETWM2OD1yLkC3NlA6KM7:TR?= NWTpSHBwW0GQR1XS
MMAC-SF MnTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jKcGlEPTB;MD6wO|I3QCEQvF2= M4WwXnNCVkeHUh?=
CP66-MEL MlTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTBwMEe1JO69VQ>? Mn6zV2FPT0WU
LB771-HNC NGjBbIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLnfXdzUUN3ME2wMlA5ODN4IN88US=> NIjyeXpUSU6JRWK=
no-10 M{XpNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;qTohKSzVyPUCuNFg6ODlizszN M2\X[3NCVkeHUh?=
A388 NHOzT5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7aTWM2OD1yLkC5NFY2KM7:TR?= Mo[3V2FPT0WU
OPM-2 MnLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTBwMUC0O|Qh|ryP NYHPcXRoW0GQR1XS
OVCAR-4 NV3vOIRXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXpXGtKSzVyPUCuNVA6OzhizszN M4fROnNCVkeHUh?=
HOP-62 NFPLT|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPVcZRyUUN3ME2wMlExQTR7IN88US=> MlzRV2FPT0WU
ML-2 NULq[pdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFexWFZKSzVyPUCuNVE5ODZizszN MXjTRW5ITVJ?
UACC-257 NEHTNYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml21TWM2OD1yLkGxPVI4KM7:TR?= M3qwNnNCVkeHUh?=
NEC8 M{nTVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGq4fIxKSzVyPUCuNVE6QTVizszN NVLKTIFFW0GQR1XS
ONS-76 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFT2cFZKSzVyPUCuNVI6OzVizszN M4rIUnNCVkeHUh?=
KE-37 MlTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjBZpNkUUN3ME2wMlE{Ojd6IN88US=> NEPvSY1USU6JRWK=
HT-144 M4W3Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjhTWM2OD1yLkGzPFk2KM7:TR?= MXfTRW5ITVJ?
LB2241-RCC NW\UWnRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPFTWM2OD1yLkG0NlQ4KM7:TR?= MUDTRW5ITVJ?
TE-5 M{XXcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTBwMUSyO|gh|ryP M{CwR3NCVkeHUh?=
KINGS-1 M3TRZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGf4[ZZKSzVyPUCuNVQ4QSEQvF2= MljrV2FPT0WU
NCI-H69 NHyyVplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTBwMUWxOFEh|ryP NYnzVVVkW0GQR1XS
CAS-1 NHP6V5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rlNGlEPTB;MD6xOVQ5OiEQvF2= NHjXRYtUSU6JRWK=
D-263MG MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTIXHM1UUN3ME2wMlE3ODB4IN88US=> MVrTRW5ITVJ?
A253 NU\uZ2tqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTBwMU[xNlgh|ryP NHvKcXFUSU6JRWK=
PF-382 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTqblBbUUN3ME2wMlE3PzB4IN88US=> MUXTRW5ITVJ?
CESS NEnFfHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TtT2lEPTB;MD6xO|A3KM7:TR?= M{O4SXNCVkeHUh?=
MZ2-MEL NH3nUlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4ftXGlEPTB;MD6xO|U2QSEQvF2= MYHTRW5ITVJ?
HEL M{XmbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTBwMUi1NVch|ryP NHTqVGlUSU6JRWK=
D-392MG MkXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTBwMUmxNVUh|ryP NX7rVIc1W0GQR1XS
SK-LMS-1 MlzGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3:1T2lEPTB;MD6xPVMxOyEQvF2= M1u3ZXNCVkeHUh?=
GI-ME-N Mk\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1f2[mlEPTB;MD6xPVMxPiEQvF2= NGLOTVRUSU6JRWK=
LB831-BLC NHvIfmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjFTWM2OD1yLkG5N|Qh|ryP NHXqV5VUSU6JRWK=
DU-4475 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzYRlluUUN3ME2wMlE6PjV6IN88US=> NYmyc5g5W0GQR1XS
IST-SL1 MkXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVq1WVVDUUN3ME2wMlIxODl2IN88US=> MYTTRW5ITVJ?
GAK NYfm[4xnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTBwMkC1N|Qh|ryP MkW3V2FPT0WU
EW-1 NXrU[JNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjyd3JKSzVyPUCuNlExPDdizszN Ml3HV2FPT0WU
LAMA-84 M{LKPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTBwMkG4OVEh|ryP M{C4PHNCVkeHUh?=
SK-UT-1 NVi0UWpsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTHXYg{UUN3ME2wMlIzODR7IN88US=> Mk[0V2FPT0WU
VA-ES-BJ MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzWcYlKSzVyPUCuNlIzPTdizszN MXTTRW5ITVJ?
ACN Ml7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTBwMkK2N|gh|ryP MkHUV2FPT0WU
SK-PN-DW NGPxSmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfIcG1KSzVyPUCuNlMyQSEQvF2= MXzTRW5ITVJ?
HD-MY-Z NFflfIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXmzeZMzUUN3ME2wMlI{OzB|IN88US=> M2DkWHNCVkeHUh?=
LB373-MEL-D MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LMcmlEPTB;MD6yOFE6QCEQvF2= NVrRfJk1W0GQR1XS
COLO-829 MoDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPETWM2OD1yLkK0NlU4KM7:TR?= NF23RYpUSU6JRWK=
ES8 NHzpU2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTBwMkS3OlMh|ryP NVfHR3RbW0GQR1XS
RXF393 M4fub2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7FTWM2OD1yLkK1NFE2KM7:TR?= Mme2V2FPT0WU
TK10 M2CwZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTBwMkW0N|Uh|ryP NEfUPGZUSU6JRWK=
LOUCY NHL1S2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTBwMkW0OVYh|ryP MnfuV2FPT0WU
MZ7-mel MmrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjwbGZKSzVyPUCuNlY{PzRizszN MkfJV2FPT0WU
CP67-MEL MonpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXnTWM2OD1yLkK2O|Mh|ryP MXrTRW5ITVJ?
C2BBe1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfHTWM2OD1yLkK3PVA4KM7:TR?= NEjUSXlUSU6JRWK=
K052 MoHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXz4dog5UUN3ME2wMlI5QTlizszN MkLIV2FPT0WU
MOLT-16 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\2N5l2UUN3ME2wMlI6PTJ2IN88US=> Ml\YV2FPT0WU
KNS-81-FD MnP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTBwM{CzNlMh|ryP MmrKV2FPT0WU
CMK NHLoNo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWK5V20zUUN3ME2wMlMyOTJizszN Mlm2V2FPT0WU
LAN-6 NX:4cWd[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfiN3lKSzVyPUCuN|E{KM7:TR?= MULTRW5ITVJ?
KLE MmLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUT1PWlzUUN3ME2wMlMyOzB4IN88US=> MnP0V2FPT0WU
NCCIT MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnu4TWM2OD1yLkOxO|g{KM7:TR?= M3H3T3NCVkeHUh?=
HH M3;pWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTBwM{K4PVch|ryP NFizUHZUSU6JRWK=
TE-8 NIDWdoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTXTWM2OD1yLkO0Nlc6KM7:TR?= Ml72V2FPT0WU
GDM-1 MlzvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnRW5pJUUN3ME2wMlM2OTB2IN88US=> MWjTRW5ITVJ?
NCI-H747 M1zYZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jCfmlEPTB;MD6zO|ExOyEQvF2= NGrheHpUSU6JRWK=
NCI-H1092 NEKySW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\IVFd7UUN3ME2wMlM5QDR2IN88US=> MoXNV2FPT0WU
8-MG-BA NI\UZY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTBwM{m4N|ch|ryP MVPTRW5ITVJ?
NB17 NVPxfGRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrRZoRNUUN3ME2wMlQzQTdizszN MnL5V2FPT0WU
LC4-1 NGr5[JBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjCXGhHUUN3ME2wMlQ{PjB5IN88US=> M4\ITHNCVkeHUh?=
TE-1 NED5[o1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjvZ2lPUUN3ME2wMlQ2OTF7IN88US=> NV3ZU5FvW0GQR1XS
KALS-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTBwNE[1PFQh|ryP NXz1fYdiW0GQR1XS
CCRF-CEM M{XqN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjzdI5KSzVyPUCuOFc3PzRizszN Mn31V2FPT0WU
OS-RC-2 M{Pld2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mne1TWM2OD1yLkS3PVczKM7:TR?= Mnf2V2FPT0WU
A704 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTBwNEi2PVIh|ryP M2n2eXNCVkeHUh?=
BB49-HNC M2LIO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnG3TWM2OD1yLkS5NFk3KM7:TR?= MVfTRW5ITVJ?
EVSA-T M3TWe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTBwNEm5NVEh|ryP MVzTRW5ITVJ?
Mo-T MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mme3TWM2OD1yLkWxO|YzKM7:TR?= MnjxV2FPT0WU
MONO-MAC-6 M3nocmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2ruRWlEPTB;MD61N|YyOSEQvF2= M1zG[XNCVkeHUh?=
BB65-RCC Ml\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\6TWM2OD1yLkW2PFEyKM7:TR?= MkL1V2FPT0WU
NCI-H1882 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEG5VXJKSzVyPUCuOVkxOzZizszN MkDyV2FPT0WU
TE-9 NH\2dI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\RToN[UUN3ME2wMlYyODN|IN88US=> MWnTRW5ITVJ?
NCI-H2126 MkfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnVbYtKSzVyPUCuOlI3PjlizszN NW[3[|NvW0GQR1XS
SF268 NVzJfnd4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLwWJFXUUN3ME2wMlY2PjRzIN88US=> MXfTRW5ITVJ?
SW872 M4LId2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEKyUVJKSzVyPUCuOlU4OjlizszN NVvCbYJHW0GQR1XS
LS-513 NVnxVHFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PCTGlEPTB;MD62Olc2OSEQvF2= NF\VdXBUSU6JRWK=
NCI-H1355 NVTlVFF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfaTWM2OD1yLk[4OlE6KM7:TR?= M1vZNHNCVkeHUh?=
BL-70 NEi0fZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTBwNkmzPFgh|ryP MV\TRW5ITVJ?
NCI-SNU-5 NWPkRmNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYS5[mtLUUN3ME2wMlY6PTR3IN88US=> MWXTRW5ITVJ?
SNU-C2B MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4[yXmlEPTB;MD63NFc{QSEQvF2= MoqwV2FPT0WU
GB-1 MlnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTBwN{KxNlQh|ryP NEjYb3ZUSU6JRWK=
CTB-1 NHO5d|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXm[5FKSzVyPUCuO|c6PTVizszN MVrTRW5ITVJ?
Becker MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7TSVdKSzVyPUCuO|k3OjFizszN MVzTRW5ITVJ?
KM12 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTTdGo3UUN3ME2wMlg2PDZ4IN88US=> MYPTRW5ITVJ?
ES7 NYnMfWdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17RWGlEPTB;MD64PVY2KM7:TR?= NY\iVZRHW0GQR1XS
COLO-684 NXfoZZV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPuRYdKSzVyPUCuPVA3PThizszN M4HrcXNCVkeHUh?=
HCC2998 NIq0THdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\u[5BKSzVyPUCuPVM5PTRizszN Mn7ZV2FPT0WU
TE-10 M1[4cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTBwOU[0N{DPxE1? MnjoV2FPT0WU
SF126 M2S4W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTBwOUi5O|Eh|ryP MkT5V2FPT0WU
EKVX MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkmxTWM2OD1zLkCzOFQzKM7:TR?= MYXTRW5ITVJ?
KARPAS-45 NXjFXXRRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTFwMESwNVYh|ryP NEfSZ2lUSU6JRWK=
KGN NWLXS5ZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mly1TWM2OD1zLkC1NFQ2KM7:TR?= Mlv0V2FPT0WU
ES1 M3frUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrVd|VNUUN3ME2xMlA4QTJzIN88US=> NFTodnFUSU6JRWK=
L-540 NXPoPHNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rOXGlEPTB;MT6xNVg{QSEQvF2= NYfHOI1ZW0GQR1XS
KURAMOCHI MnLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFH1RlRKSzVyPUGuNVI{PzRizszN NUjYeHFTW0GQR1XS
LU-65 M{HsTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\McnJsUUN3ME2xMlEzPzV|IN88US=> NGD4XXhUSU6JRWK=
MFH-ino NH3MTG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTFwMUe1NFEh|ryP NVTpbI02W0GQR1XS
NCI-H23 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTpe4VKSzVyPUGuNlA1OSEQvF2= NETjOYxUSU6JRWK=
IA-LM NXfTZlRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTFwMkSxNVYh|ryP NEjZXXpUSU6JRWK=
PSN1 M3fzVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTJNFRKSzVyPUGuNlcxOTZizszN NYPIPZNoW0GQR1XS
NCI-H719 NFLMPZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTFwMke0NVEh|ryP M{js[HNCVkeHUh?=
SW684 NWOwTpRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTJRWtKSzVyPUGuNlg3PTlizszN NUmxOXFkW0GQR1XS
HCE-4 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moq0TWM2OD1zLkOwNlIyKM7:TR?= M{Lw[3NCVkeHUh?=
EW-16 NE\UWplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LweWlEPTB;MT6zNVM1PyEQvF2= MUHTRW5ITVJ?
NCI-H128 NUDjfG9QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\3RYdKSzVyPUGuN|U5OTRizszN MVjTRW5ITVJ?
HC-1 M2f6NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\QRWlEPTB;MT6zPFE4KM7:TR?= NFfvZ4dUSU6JRWK=
IST-MES1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTFwNECyNFgh|ryP M163VXNCVkeHUh?=
Raji MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTFwNEG4OUDPxE1? M4\UbXNCVkeHUh?=
DMS-114 MmXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;xZm54UUN3ME2xMlQ1PTN7IN88US=> NWC2RlhmW0GQR1XS
GI-1 NUC2eolUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTFwNEexN|Eh|ryP M3K1fHNCVkeHUh?=
NCI-H2081 M2qzRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTEV|k{UUN3ME2xMlU2OTl4IN88US=> M33pcHNCVkeHUh?=
LC-1F MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfWTo5KSzVyPUGuOVUyQThizszN NXewfIt3W0GQR1XS
NCI-H2227 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHme3lKSzVyPUGuOlE2PjFizszN M3r0TnNCVkeHUh?=
D-502MG NHGzbFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\PRWlEPTB;MT62O|IyOSEQvF2= NXO5fJRoW0GQR1XS
NCI-H2141 NFPWTmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEm1fIdKSzVyPUGuOlc{OTdizszN NX7xZm9DW0GQR1XS
LS-411N NYTQXY5GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nHb2lEPTB;MT62PVgxPyEQvF2= M4XrfHNCVkeHUh?=
SU-DHL-1 M1zMOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTFwN{GyPFEh|ryP M3[zT3NCVkeHUh?=
BB30-HNC NETSTmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M32yZmlEPTB;MT63NlY5PSEQvF2= NUfOXJdHW0GQR1XS
TE-15 NIiyXFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXj1WGI{UUN3ME2xMlkzOzd|IN88US=> MlLNV2FPT0WU
JVM-3 NIjIfVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLWeVhKSzVyPUGuPVM6ODRizszN NWKzUmxZW0GQR1XS
IST-SL2 M3\X[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTJwMEGyOVIh|ryP NGTBZ5hUSU6JRWK=
EW-18 NH;5fXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTJwMEKzN|ch|ryP NXj4bJhpW0GQR1XS
DJM-1 NEW3U4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHL6VFFKSzVyPUKuNFI2PTJizszN NFOwc5hUSU6JRWK=
no-11 M1K0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHSXYZKSzVyPUKuNFMyODRizszN MVTTRW5ITVJ?
QIMR-WIL M1rVUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLncJRKSzVyPUKuNVY4PjJizszN M1rObXNCVkeHUh?=
MC-CAR M4GyTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTJwMkK5OUDPxE1? MWPTRW5ITVJ?
KM-H2 NGjBSmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2roOGlEPTB;Mj6yPVA1OyEQvF2= NVPMTWtWW0GQR1XS
ECC12 Mm\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HjTGlEPTB;Mj6zO|k1KM7:TR?= NX70UFRNW0GQR1XS
HCE-T NEPKTJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zTc2lEPTB;Mj60OFg5OyEQvF2= M1HlSHNCVkeHUh?=
MFM-223 M1XoV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDuNpp7UUN3ME2yMlUxQDdzIN88US=> NEnnS|NUSU6JRWK=
SW982 NX\IPJlNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TNTmlEPTB;Mj61NVQ5KM7:TR?= NUjxNWJ4W0GQR1XS
KG-1 M4fvVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUniVJhUUUN3ME2yMlg5PzlzIN88US=> Ml\6V2FPT0WU
ES4 M4jBRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HXbGlEPTB;Mz6wOlEyOSEQvF2= NHHiSXZUSU6JRWK=
SCC-3 MnzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmT4TWM2OD1|LkGwPFQ5KM7:TR?= NYHxe3ZnW0GQR1XS
RH-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;RVGlEPTB;Mz6zPFc1QCEQvF2= MVnTRW5ITVJ?
NCI-H748 M4jSSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLkWFhRUUN3ME2zMlQ1OjZ4IN88US=> M3faTnNCVkeHUh?=
HCC2218 NIO4VldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIm3bHhKSzVyPUOuOFY6OzdizszN MYDTRW5ITVJ?
MEG-01 NEXwZnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTNwNUm2PEDPxE1? NEL3XWxUSU6JRWK=
NB12 NXnmc2U5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nmRWlEPTB;Mz61PVg5QCEQvF2= MVHTRW5ITVJ?
SNB75 M{K3Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPSTWM2OD1|Lk[wNVA{KM7:TR?= NVPUdY5zW0GQR1XS
KMS-12-PE MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LGTWlEPTB;Mz62O|czOyEQvF2= M4PtdHNCVkeHUh?=
SKM-1 M2\pWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTNwN{GzO|Yh|ryP MV\TRW5ITVJ?
COLO-320-HSR MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjVfVlTUUN3ME2zMlc2PjN2IN88US=> NVnFeZRNW0GQR1XS
NKM-1 Ml7uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV:x[JZEUUN3ME2zMlc4Ozd6IN88US=> NF2xPZBUSU6JRWK=
TE-6 NWDEV|FCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDCNHhKSzVyPUOuPVQ2PjFizszN MXvTRW5ITVJ?
D-336MG NFHxU|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYi0cpNPUUN3ME20MlAyOTZ4IN88US=> M4rzT3NCVkeHUh?=
NCI-H1650 NYjF[3hGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmruTWM2OD12LkG1O|k4KM7:TR?= M2e3bHNCVkeHUh?=
ES3 M{HFZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPGTWM2OD12LkOyPFI1KM7:TR?= NX22bnpWW0GQR1XS
YT NUnWd4NbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTRwM{W0NlQh|ryP M4D1[HNCVkeHUh?=
ES5 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jVW2lEPTB;ND60NFI2PSEQvF2= MWLTRW5ITVJ?
LB647-SCLC NXHKN2V2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml[yTWM2OD12LkW2N|A5KM7:TR?= MonMV2FPT0WU
HAL-01 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PaT2lEPTB;ND61O|A{PCEQvF2= MmO4V2FPT0WU
LP-1 NGfrSo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PtXGlEPTB;ND63NlM4OSEQvF2= NWjWOmZJW0GQR1XS
BC-1 NG\F[HpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfiSFlKSzVyPUWuNFA1PDdizszN MUfTRW5ITVJ?
EB-3 M2jPUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvTTWM2OD13LkCzNFQyKM7:TR?= NXvJXGFCW0GQR1XS
GT3TKB NG\rc41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\MVWlEPTB;NT6xO|Y3OiEQvF2= MVLTRW5ITVJ?
NCI-H209 NETO[5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1r1OGlEPTB;NT6xPVM2OiEQvF2= MUDTRW5ITVJ?
BT-474 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnKxTWM2OD13LkKzNVAzKM7:TR?= MYTTRW5ITVJ?
RKO MmLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rRU2lEPTB;NT6yN|QzOiEQvF2= M1HQTnNCVkeHUh?=
SIMA NITvcm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTVwM{C3OlUh|ryP M1vrZ3NCVkeHUh?=
RL NIHqWpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHwc3pKSzVyPUWuN|c2PDFizszN Mlv3V2FPT0WU
GCIY MnGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1znZmlEPTB;NT60O|I{PiEQvF2= NITFc2FUSU6JRWK=
Calu-6 MnLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXq5flFjUUN3ME21MlYzOiEQvF2= MXnTRW5ITVJ?
ALL-PO NUnYU|ZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTVwNkO3PVUh|ryP M{i0NnNCVkeHUh?=
ARH-77 NX7vRnh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkexTWM2OD13Lk[3NFg4KM7:TR?= M{e0[3NCVkeHUh?=
A4-Fuk Ml\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTZwMEixNVgh|ryP M1[xTXNCVkeHUh?=
NCI-H1581 M1frdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofZTWM2OD14LkKzPFQ6KM7:TR?= MUPTRW5ITVJ?
HUTU-80 MkPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{CyeWlEPTB;Nj6zOlg6PyEQvF2= M{\BTXNCVkeHUh?=
TGW MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzEW5ZbUUN3ME22MlQ2PTl|IN88US=> M{\vd3NCVkeHUh?=
SK-N-FI NF3IOmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zrTGlEPTB;Nj60OVg2PCEQvF2= M3:3PXNCVkeHUh?=
U-266 Mm\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\IN5hKSzVyPU[uOVE6OjZizszN MlnqV2FPT0WU
EM-2 MonkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;yRYJKSzVyPU[uOlcxQTlizszN M{jGfnNCVkeHUh?=
NMC-G1 NIj0cJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTZwN{G4PVUh|ryP NVXDOGtCW0GQR1XS
KASUMI-1 MoDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkS5TWM2OD14Lki0O|g4KM7:TR?= NXLVVot5W0GQR1XS
NALM-6 NIPJNYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3ETWM2OD14Lki2O|U1KM7:TR?= NVvWRnBXW0GQR1XS
OCI-AML2 M4jxOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37jN2lEPTB;Nz6wNFMzPiEQvF2= NGXDc4FUSU6JRWK=
SHP-77 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7Gc3pbUUN3ME23MlIzPDNizszN NXz4O4RLW0GQR1XS
NOMO-1 M{LEVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVezdmpqUUN3ME23MlI1OjV2IN88US=> NET6c3hUSU6JRWK=
SK-N-DZ MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NICy[XRKSzVyPUeuO|ExQDlizszN NXrlcmg5W0GQR1XS
LB1047-RCC M{TSUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTdwN{KyN|Eh|ryP MlvsV2FPT0WU
MZ1-PC MoPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\1TGlEPTB;Nz64OlU2QCEQvF2= M2izWnNCVkeHUh?=
NB10 NHr3SpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfKTWM2OD15Lkm5OVU3KM7:TR?= M4HYPHNCVkeHUh?=
RL95-2 Ml3uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\mXINKSzVyPUiuNVA5PDJizszN MYTTRW5ITVJ?
OMC-1 NGrONWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm[0TWM2OD16LkWyNVkyKM7:TR?= NX3GWWVNW0GQR1XS
D-283MED Mn3ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDmTWM2OD16LkmxO|E6KM7:TR?= Mn\xV2FPT0WU
MC116 M4PjZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHMOZBKSzVyPUiuPVc6PCEQvF2= MX7TRW5ITVJ?
SJSA-1 NUHK[2dZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvmRlFUUUN3ME25MlA6ODlzIN88US=> NXz2SWFtW0GQR1XS
JiyoyeP-2003 M2\1Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TKR2lEPTB;OT6yPVMyPyEQvF2= NYi1e29UW0GQR1XS
IST-MEL1 NWH0bGNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jnRWlEPTB;OT63OFE6QCEQvF2= NWTmS44{W0GQR1XS
CTV-1 NVXUdXlRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonUTWM2OD1zMD6wPVc6KM7:TR?= M4TudXNCVkeHUh?=
NH-12 NX;YdW5iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3K4[WlEPTB;MUCuNlQ{OyEQvF2= MV7TRW5ITVJ?
CA46 NYi0Toh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfkTWM2OD1zMD6zOlEh|ryP NXvrV4kxW0GQR1XS
NCI-SNU-1 NF;pcYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTCTWM2OD1zMD60PVY6KM7:TR?= M4H0SnNCVkeHUh?=
SCLC-21H MlrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYe2[ZR1UUN3ME2xNE43PTl4IN88US=> NEXrd|hUSU6JRWK=
EC-GI-10 NWLqfG4{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTFyLkewN|Eh|ryP MnXDV2FPT0WU
SR Mo\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2roW2lEPTB;MUGuNFE5PSEQvF2= MlXvV2FPT0WU
NCI-H1648 M3LZWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTFzLkC5OlUh|ryP NGLCeJNUSU6JRWK=
TGBC1TKB NVThOoNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnic2p5UUN3ME2xNU41OTB{IN88US=> NXzvRoZ5W0GQR1XS
EW-11 M3P5NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjFdI5KSzVyPUGxMlUyQDZizszN MYTTRW5ITVJ?
SK-MM-2 NW\DRlh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLh[2lIUUN3ME2xNU45ODZzIN88US=> NV2wOlNZW0GQR1XS
NCI-H524 NIrMbHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LyU2lEPTB;MUGuPVgzOiEQvF2= M3jGTXNCVkeHUh?=
NOS-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTF{LkCzOFUh|ryP Ml7MV2FPT0WU
AM-38 M{DlUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TsRWlEPTB;MUKuOVY{OyEQvF2= MnjPV2FPT0WU
A498 Mkj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFu1XWtKSzVyPUGyMlcxPjlizszN NFvYXXhUSU6JRWK=
KARPAS-422 M2PQSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\ibWlEPTB;MUKuO|Q6PiEQvF2= NHHEZopUSU6JRWK=
LU-139 NFL2TZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDH[GxKSzVyPUGyMlkxOjZizszN NXHhUVY1W0GQR1XS
COR-L88 MoHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXGxOml1UUN3ME2xNk46Ozh{IN88US=> M{n6O3NCVkeHUh?=
K5 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHBRYtKSzVyPUGyMlk1PjJizszN MV3TRW5ITVJ?
NB13 MmTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPQWYZKSzVyPUGyMlk4QDNizszN M{PJN3NCVkeHUh?=
MRK-nu-1 MnrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlT1TWM2OD1zMz6xPVUh|ryP NX74VWNuW0GQR1XS
MHH-NB-11 MmHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDHTWM2OD1zMz6yPVAzKM7:TR?= MV3TRW5ITVJ?
KU812 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFu1RmxKSzVyPUGzMlYyOjRizszN M4PtcXNCVkeHUh?=
TE-12 MmTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoP3TWM2OD1zMz62PVk1KM7:TR?= NWnBWIp3W0GQR1XS
NCI-N87 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\ndHAzUUN3ME2xN{44OzZizszN M1n5RnNCVkeHUh?=
EB2 M2TTeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHFTWM2OD1zMz64OVA2KM7:TR?= NGfTZnVUSU6JRWK=
DB NXPLVmFST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XSNmlEPTB;MUOuPVg5PSEQvF2= MX3TRW5ITVJ?
697 NHrlT4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfnTWM2OD1zND60OVEyKM7:TR?= MVvTRW5ITVJ?
MSTO-211H MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITnRWJKSzVyPUG0Mlc1PDhizszN MnfWV2FPT0WU
JVM-2 Mn;GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTF2Lke3N|Uh|ryP MnPRV2FPT0WU
COLO-824 NELWNIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTsSIlYUUN3ME2xOE44QTl2IN88US=> NF63WpJUSU6JRWK=
BC-3 M{XEWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUmzNIt{UUN3ME2xOU4{QThizszN MV3TRW5ITVJ?
BOKU NWn0UWVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTF3Lkm2NFgh|ryP NG\ZeIZUSU6JRWK=
GOTO MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFu0OmRKSzVyPUG2Mlk3OTdizszN NHfITWtUSU6JRWK=
HCC2157 NUnzfI5HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPvVWFKSzVyPUG3MlQ4PTVizszN Mlf4V2FPT0WU
LS-1034 NIfVc4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjmRXRKSzVyPUG3MlY5OThizszN MmX1V2FPT0WU
CAL-148 MlvES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTF5Lkm3PVYh|ryP MX\TRW5ITVJ?
MOLT-4 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjjTWM2OD1zOD64NlA5KM7:TR?= NWrQPVF{W0GQR1XS
Daudi M3nP[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M360[GlEPTB;MUiuPVI{OSEQvF2= MWjTRW5ITVJ?
J-RT3-T3-5 NVGzcVlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTF7LkSwOlYh|ryP M2\l[nNCVkeHUh?=
KMOE-2 M{fxe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEniU5BKSzVyPUG5MlY1QDJizszN Ml[xV2FPT0WU
HL-60 NUTaelZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHyTWM2OD1{MD6xPVY2KM7:TR?= NFrOSItUSU6JRWK=
P31-FUJ NVn4VpBGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TQXmlEPTB;MkCuOFc2OyEQvF2= MmnlV2FPT0WU
IM-9 NEiwcldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1POUmlEPTB;MkCuOlIzPCEQvF2= NXrTRnVyW0GQR1XS
HDLM-2 NVrBZm51T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTJyLki4NlEh|ryP Mm\KV2FPT0WU
NCI-H1304 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoT2TWM2OD1{MT6wN|EyKM7:TR?= M4TNNnNCVkeHUh?=
NCI-H345 NEPHeGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFX0VlZKSzVyPUKxMlA3PDNizszN NFHQZ2NUSU6JRWK=
RPMI-6666 NYLFSHZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TLV2lEPTB;MkGuN|YxOiEQvF2= NYOyUY1nW0GQR1XS
GR-ST NHPqNnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvlTWM2OD1{MT60NVch|ryP M2rLXnNCVkeHUh?=
CHP-126 NXHLXlh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTJzLk[xPFEh|ryP NYqyO3NqW0GQR1XS
EHEB MorHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjk[mk4UUN3ME2yNU43PzNzIN88US=> M17De3NCVkeHUh?=
CPC-N MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTJ2LkCyNFEh|ryP M2DwfXNCVkeHUh?=
NB1 M2nY[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nSPGlEPTB;MkSuOlk{QSEQvF2= M1XofnNCVkeHUh?=
LS-123 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHLTWM2OD1{ND65NFEzKM7:TR?= M1zTTnNCVkeHUh?=
ST486 MkLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTJ3LkGxNVMh|ryP M2nFXnNCVkeHUh?=
NCI-H1963 MonsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHJS4NuUUN3ME2yOk4xPjJ|IN88US=> MYPTRW5ITVJ?
U-87-MG M1TtfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXWNXdSUUN3ME2yOk44PjR2IN88US=> NFXRWVdUSU6JRWK=
COR-L279 MnHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorDTWM2OD1{Nj63PVIzKM7:TR?= NFLDb5VUSU6JRWK=
LU-165 M2fQN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHrWZNKSzVyPUK4MlA5PjFizszN MkjtV2FPT0WU
COLO-800 NIPyelRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTJ6LkK5OVYh|ryP M2rCNnNCVkeHUh?=
ETK-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDiZ4xKSzVyPUK4MlM1PDZizszN MmL4V2FPT0WU
LNCaP-Clone-FGC NYK1PZQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\DeZFKSzVyPUK5MlkzQDFizszN MXjTRW5ITVJ?
SIG-M5 NHryZ|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFu5[opKSzVyPUOwMlc6PTJizszN MX7TRW5ITVJ?
NB6 MnLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLqTWM2OD1|MD65OVA{KM7:TR?= NW\0WWJ1W0GQR1XS
NCI-H2107 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TufWlEPTB;M{GuNlM{QCEQvF2= MnvVV2FPT0WU
SNU-C1 NFjz[YFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nj[2lEPTB;M{GuN|EzPiEQvF2= MlPCV2FPT0WU
JAR NELVNndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTNzLkO3PVkh|ryP MVTTRW5ITVJ?
L-363 M3TTSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmK1TWM2OD1|Mj6yNVQ1KM7:TR?= MmHDV2FPT0WU
EW-24 NVqxZW92T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHGeppKSzVyPUOyMlM1PzRizszN MoTwV2FPT0WU
NB69 NXizU3djT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYj3dGROUUN3ME2zN{43PDV2IN88US=> NF7VeFNUSU6JRWK=
EW-13 MkHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3ETWM2OD1|Mz64PVY6KM7:TR?= NYj6eItEW0GQR1XS
Ramos-2G6-4C10 NEKzZXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTN2LkK5PVMh|ryP MVfTRW5ITVJ?
TE-11 MkLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTN2LkS4NlIh|ryP MVPTRW5ITVJ?
L-428 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVz2Wm86UUN3ME2zOE44PTN4IN88US=> NHvt[JhUSU6JRWK=
KP-N-YN NVz4emt5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTN2LkmwOVch|ryP M3LuRXNCVkeHUh?=
CGTH-W-1 M3z3bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHGyW|BKSzVyPUO2MlkxPDhizszN MmruV2FPT0WU
K-562 NVvseZcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVq2c|F3UUN3ME2zO{4xQDZ2IN88US=> MWXTRW5ITVJ?
NCI-H1299 M4PkOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvqVFFKSzVyPUO4MlE3ODNizszN MlHIV2FPT0WU
RCC10RGB NITNSodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTN6LkKwPFMh|ryP M1rSUXNCVkeHUh?=
NCI-SNU-16 M2PYNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrMeo94UUN3ME2zPE42PjV|IN88US=> M1TtW3NCVkeHUh?=
LC-2-ad M2rJWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHP3cVlKSzVyPUO5MlQ{OzdizszN MYLTRW5ITVJ?
MHH-PREB-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvD[4F2UUN3ME2zPU44Ozh6IN88US=> Mmj6V2FPT0WU
NCI-H64 Mmn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTRyLkC5OFgh|ryP MYXTRW5ITVJ?
LB996-RCC MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2qwS2lEPTB;NECuPFcyPiEQvF2= MYjTRW5ITVJ?
DEL NILZZmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnnVHdsUUN3ME20NU41PDB3IN88US=> Ml3FV2FPT0WU
MLMA NH7G[FNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTRzLke1PVUh|ryP MXPTRW5ITVJ?
SBC-1 M3f0d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFW4PXRKSzVyPUSyMlE5ODZizszN MXjTRW5ITVJ?
MPP-89 NEfsUZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTR{LkW4O|Uh|ryP M{XSRnNCVkeHUh?=
MV-4-11 NVPGd5ZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVztcI1[UUN3ME20Nk46ODZ5IN88US=> NYHkSYE3W0GQR1XS
EoL-1- NIfkPZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTR2LkG1Olgh|ryP NG\jboRUSU6JRWK=
CW-2 NYD2VIp2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHf4[FhKSzVyPUS0Mlg{PDJizszN NY\vXIhVW0GQR1XS
HT MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHXPYVKUUN3ME20OU44ODB5IN88US=> NF;SWodUSU6JRWK=
SW954 M1HrNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTR5LkSxNlgh|ryP M3fzc3NCVkeHUh?=
A3-KAW M3XZZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTR7LkiwOlEh|ryP M2LGPXNCVkeHUh?=
TC-YIK M{T2Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfXUmtKSzVyPUWwMlA{PjNizszN MnHMV2FPT0WU
SW962 M3TlTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHr0[2xKSzVyPUW0Mlg{PTdizszN NVjB[XpyW0GQR1XS
KP-N-RT-BM-1 NY\GXIZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDZTWM2OD13Nj62OlM5KM7:TR?= M1qzdHNCVkeHUh?=
NCI-H1395 NGHLXnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\BNmlEPTB;NUiuPFE4OiEQvF2= MlHsV2FPT0WU
RPMI-8402 NILuTpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7qTWM2OD13OD65OVI3KM7:TR?= NHG2WoRUSU6JRWK=
SCH M{W0VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTZyLkm2N|gh|ryP M1;VU3NCVkeHUh?=
NCI-H2196 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTZzLkKzNUDPxE1? NHntfnBUSU6JRWK=
LOXIMVI NGjQcJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nwXGlEPTB;NkGuPFI3PiEQvF2= NV2yXpFkW0GQR1XS
TGBC24TKB MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoC1TWM2OD14Mj6xOFkyKM7:TR?= MWTTRW5ITVJ?
SK-MEL-2 NVLHbY9JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTZ|Lkm4PVIh|ryP MnnBV2FPT0WU
U-698-M MnnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTMTWM2OD14OD61Olg4KM7:TR?= MX3TRW5ITVJ?
NCI-H1522 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTZ7LkCwOFch|ryP M4W5fXNCVkeHUh?=
UACC-812 NV7qVmpjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jzZmlEPTB;NkmuOVIxQSEQvF2= MonEV2FPT0WU
MHH-CALL-2 M1jjS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13QbGlEPTB;N{CuNFYh|ryP NIG4Om1USU6JRWK=
NB5 NGOzOVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fYe2lEPTB;N{CuN|Q3QCEQvF2= NIjoWYpUSU6JRWK=
KARPAS-299 Mn;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTdyLkS0OFch|ryP MXrTRW5ITVJ?
NCI-H1694 Mmr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHSSWhDUUN3ME23NU4xOzJizszN MVXTRW5ITVJ?
NCI-H82 MmTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HJZmlEPTB;N{GuPVUxPyEQvF2= NVHrWI1XW0GQR1XS
SCC-15 NYPxS2pmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIe3T4lKSzVyPUeyMlM1KM7:TR?= M{nE[nNCVkeHUh?=
NCI-H1436 NWDJWXN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTZbJlKSzVyPUeyMlc1PTZizszN MYnTRW5ITVJ?
ATN-1 NVvTcXRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnoO2RKSzVyPUe0MlUxPSEQvF2= NEnkRXBUSU6JRWK=
RPMI-8866 Ml;pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTd2Lke1NFkh|ryP MWrTRW5ITVJ?
HCC1599 NHzmeGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvZTWM2OD15ND64O|MzKM7:TR?= MnTjV2FPT0WU
NCI-H1155 NHn1cHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEG3[FNKSzVyPUe0Mlk{PjdizszN NFr0RldUSU6JRWK=
DOHH-2 NWG1dHgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDyPVdKSzVyPUe0Mlk2OTRizszN NXH3N|R3W0GQR1XS
SK-NEP-1 NIrSS5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XOSmlEPTB;N{WuNFc2PCEQvF2= MUfTRW5ITVJ?
HCC1187 NH\wPHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoK1TWM2OD15Nz62NVIzKM7:TR?= NV;LfoIzW0GQR1XS
NCI-H322M NFXmNYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTd6LkO3NFkh|ryP MkXWV2FPT0WU
NCI-H526 Ml[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTJRYNnUUN3ME23PE42QDd5IN88US=> M4jhTXNCVkeHUh?=
NCI-H2171 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTd7LkSxN|Yh|ryP M2LUUHNCVkeHUh?=
COLO-668 M2O5NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoiyTWM2OD16MT61PFg1KM7:TR?= MoLqV2FPT0WU
RS4-11 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFX1TllKSzVyPUiyMlI2ODVizszN M4j0bXNCVkeHUh?=
NCI-H716 NXXzPIg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfPTmFwUUN3ME24Nk46ODd3IN88US=> NYrGVGQ{W0GQR1XS
LU-134-A MkDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1:3emlEPTB;OEOuNVM2OSEQvF2= NEjzPJVUSU6JRWK=
RPMI-8226 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4H6OmlEPTB;OESuNlExPyEQvF2= M3izdXNCVkeHUh?=
KY821 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\XTZVKSzVyPUmxMlY2PTFizszN NXnCfpUxW0GQR1XS
ECC4 NVTBfIJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrGeZRKSzVyPUmzMlgzPjlizszN MmjnV2FPT0WU
EW-3 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHCRXNtUUN3ME25OE46ODhzIN88US=> MlPNV2FPT0WU
NB7 NVnjSm97T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzYTWM2OD17NT63O|g3KM7:TR?= NYHUW5h7W0GQR1XS
NCI-H720 NF7qOoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTl6LkSwOlEh|ryP NV7tdIF6W0GQR1XS
NCI-H446 NFy2eZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\0TWM2OD17OT63OVg5KM7:TR?= MYnTRW5ITVJ?
NCI-H889 NXThPGpJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTFyND6yOFIh|ryP MkXQV2FPT0WU
EW-22 Mo\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfJ[FBtUUN3ME2xNFYvOTlizszN MmXTV2FPT0WU
BV-173 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4f1NWlEPTB;MUC4MlczQCEQvF2= MljNV2FPT0WU
WSU-NHL NIexbnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTFyOT62O|Eh|ryP Mli3V2FPT0WU
MN-60 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;UbmlEPTB;MUC5MlY6KM7:TR?= MVTTRW5ITVJ?
DG-75 MlX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkm5TWM2OD1zMUOuN|UzKM7:TR?= NH7XZlFUSU6JRWK=
DMS-79 NXLjO4JZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PrXmlEPTB;MUG3MlM5OiEQvF2= MlrZV2FPT0WU
SK-MEL-1 MoXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjSfJVKSzVyPUGxPE4xODlizszN Ml7rV2FPT0WU
DMS-153 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofHTWM2OD1zMkGuO|Q2KM7:TR?= MWLTRW5ITVJ?
NCI-H510A NUfyUVFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYn0OYJTUUN3ME2xNlcvOzJizszN NYDI[WpQW0GQR1XS
BE-13 M3rmNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XrNGlEPTB;MUO0MlA1PCEQvF2= Mk\SV2FPT0WU
KP-N-YS M1\rfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXnXGFKSzVyPUGzPU44OzZizszN M3j4b3NCVkeHUh?=
SUP-T1 NVq3SndjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofFTWM2OD1zNEOuO|A5KM7:TR?= NFfaN5pUSU6JRWK=
EW-12 NUTGUXFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXWZ2d5UUN3ME2xOFQvPjl7IN88US=> NY\WXXRrW0GQR1XS
NB14 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\6TWlEPTB;MUS3MlA5OiEQvF2= MU\TRW5ITVJ?
MDA-MB-134-VI NYja[243T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHlRlJNUUN3ME2xOFgvOjZ6IN88US=> MUXTRW5ITVJ?
NCI-H1770 M2D3dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnUOItKSzVyPUG1Ok4zPzlizszN MUjTRW5ITVJ?
TUR MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTF4Nz64O{DPxE1? NF6xVldUSU6JRWK=
NCI-H1417 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7rTWM2OD1zOECuN|MyKM7:TR?= MYfTRW5ITVJ?
IMR-5 NYTJOnp1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vNNWlEPTB;MUixMlU4OSEQvF2= NVr1N2RvW0GQR1XS
NCI-H226 M4La[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3Ed5lKSzVyPUG4PE45PjZizszN MVzTRW5ITVJ?
NCI-H187 NXrDW5JIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoT1TWM2OD1zOUCuNFY1KM7:TR?= MX\TRW5ITVJ?
SF539 MlGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnJR4tFUUN3ME2xPVIvPzJ6IN88US=> MWHTRW5ITVJ?
TALL-1 NHjRTIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPMTWM2OD1zOUiuN|A1KM7:TR?= M1;2NHNCVkeHUh?=
TE-441-T MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33CZmlEPTB;MUm5Mlc{QSEQvF2= MWrTRW5ITVJ?
REH MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTJ|Nj62NlYh|ryP MorZV2FPT0WU
MS-1 NInlN4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3D[21KSzVyPUKzPU4yOjFizszN NELSO4NUSU6JRWK=
THP-1 NHKyVGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2iyNWlEPTB;Mk[0Mlc{QCEQvF2= MV3TRW5ITVJ?
NCI-H1838 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TBPGlEPTB;MkexMlQ2PiEQvF2= MXPTRW5ITVJ?
P30-OHK M1rsVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPRS25KSzVyPUK4N{45PDdizszN M{jy[nNCVkeHUh?=
C8166 Mnv0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTN2NT6zN|gh|ryP MlvTV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western Blot
Bcr-Abl; 

PubMed: 26722260     


(C) K562 cells were treated with SAHA (1 µM or 2 µM), MG-132 (400 nM) or SAHA plus MG-132 (400 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. (D) K562G cells were treated with SAHA (1 µM or 2 µM), MG-132 (200 nM) or SAHA plus MG-132 (200 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. Representative blots from three independent experiments are shown.

Ac-histone H3; 

PubMed: 26722260     


(C) K562 cells were treated with SAHA (1 µM or 2 µM), MG-132 (400 nM) or SAHA plus MG-132 (400 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. (D) K562G cells were treated with SAHA (1 µM or 2 µM), MG-132 (200 nM) or SAHA plus MG-132 (200 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. Representative blots from three independent experiments are shown.

Cleaved-caspase3; 

PubMed: 26722260     


(C) K562 cells were treated with SAHA (1 µM or 2 µM), MG-132 (400 nM) or SAHA plus MG-132 (400 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. (D) K562G cells were treated with SAHA (1 µM or 2 µM), MG-132 (200 nM) or SAHA plus MG-132 (200 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. Representative blots from three independent experiments are shown.

Cleaved-PARP; 

PubMed: 26722260     


(C) K562 cells were treated with SAHA (1 µM or 2 µM), MG-132 (400 nM) or SAHA plus MG-132 (400 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. (D) K562G cells were treated with SAHA (1 µM or 2 µM), MG-132 (200 nM) or SAHA plus MG-132 (200 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. Representative blots from three independent experiments are shown.

ASCL1; 

PubMed: 19765735     


MG-132 decreases the levels of ASCL1 and CgA in carcinoid cancer cells. Pulmonary (NCI-H727) (A) carcinoid cancer cells were treated with MG-132 (0 to 4µM) for 48 hours and cell lysates were analyzed by Western blotting for the expression of ASCL1 and CgA. Treatment with MG-132 results in a dose dependent inhibition of the two neuroendocrine tumor markers. Analysis for GAPDH confirmed equal loading.

CgA; 

PubMed: 19765735     


MG-132 decreases the levels of ASCL1 and CgA in carcinoid cancer cells. Pulmonary (NCI-H727) (A) carcinoid cancer cells were treated with MG-132 (0 to 4µM) for 48 hours and cell lysates were analyzed by Western blotting for the expression of ASCL1 and CgA. Treatment with MG-132 results in a dose dependent inhibition of the two neuroendocrine tumor markers. Analysis for GAPDH confirmed equal loading.

Nrf2; 

PubMed: 23604711     


MG-132 stimulates Nrf2 and HO-1 protein expression in HAECs in a time-dependent fashion. Cells were treated with MG-132 (2 μM) for various times (0–24 h), and Nrf2 and HO-1 protein were quantified by scanning densitometry, normalized with respect to β-actin, and expressed relative to those of control cells.

HO-1; 

PubMed: 23604711     


MG-132 stimulates Nrf2 and HO-1 protein expression in HAECs in a time-dependent fashion. Cells were treated with MG-132 (2 μM) for various times (0–24 h), and Nrf2 and HO-1 protein were quantified by scanning densitometry, normalized with respect to β-actin, and expressed relative to those of control cells.

26722260 19765735 23604711
Immunofluorescence
C2GnT-M / NMIIA; 

PubMed: 22525330     


Confocal images of bC2GnT-M and NMIIA in cells treated with DMSO (D) or MG-132 (E).

AGS3 / Vimentin; 

PubMed: 20065032     


COS-7 cells were transfected with wild-type or TPR-modified AGS3 (AGS3-TPR [M1 to E470] or AGS3-GPR [E470 to S650]) in pEGFP-N1. Thirty-six hours after transfection, cells were incubated with MG 132 (10 μM) for 12 h, and then the cells were processed for immunofluorescence microscopy. The images presented are representative of 2 to 10 separate transfections.

Bak; 

PubMed: 20557369     


Proteasome inhibitor induces Bak activation. Cells were treated with either vehicle or MG-132 at 10 µmol/L for 12 hours and were subjected to Bak immunofluorescence study using antiserum specific for the N terminus of Bak. Upon Bak activation, this epitope is no longer masked within the protein and becomes available for antibody binding upon Bak conformational change.

22525330 20065032 20557369
Growth inhibition assay
Apoptosis assay; 

PubMed: 20557369     


LX-2 cells were incubated for 24 hours in the presence of increasing concentrations of MG-132 (0, 2.5, 5, 10 µmol/L) and in the presence of the pan-caspase inhibitor QVD at 5 µmol/L for 24 hours. MG-132 and QVD were prepared in DMSO as a vehicle. All data were expressed as mean ± standard error from three individual experiments. * p < 0.01 (10 µmol/L MG-132 treated cells vs. 10 µmol/L MG-132 plus QVD treated cells)

Cell viability; 

PubMed: 26137056     


The proteasome inhibitor MG-132 significantly decreased the cell viability in EC9706 cells in a dose- and time-dependent manner.

cell proliferation ; 

PubMed: 19765735     


MG-132 significantly inhibits growth of carcinoid tumor cells in vitro. Pulmonary (NCI-H727) and GI (BON) carcinoid tumor cells were treated with MG-132 at the indicated concentrations (0 to 4µM) for up to 6 days and cell viability was measured every 2 days with the MTT assay (P<0.001). The results show that MG-132 leads to the suppression cellular proliferation in NCI-H727 (A) and BON (B) cells. (OD, optical density)

20557369 26137056 19765735
ELISA
IL-8; 

PubMed: 11160671     


ELISA of IL-8 from supernatant of eTat cells. eTat cells were blocked with Hu (2 mM) and released. MG-132 (50 μM) was added at the time of release. The supernatant was collected at 3 h postrelease and analyzed for IL-8 protein using ELISA. The result shown is representative of three independent experiments ± standard deviation. 

IL-1beta; 

PubMed: 22606244     


LPS-primed WT BMDM were incubated in control medium or medium containing 10 ng/ml ricin or 25 µg/ml cycloheximide for 4 h. MG-132 (30 µM) or Bortezimib (0.5 µM) was included as indicated. Secreted IL-1ß was measured by ELISA in triplicate wells.

11160671 22606244
In vivo

Administration of MG-132 effectively rescues the expression levels and plasma membrane localization of dystrophin, β-dystroglycan, α-bdystroglycan, and α-sarcoglycan in skeletal muscle fibers from mdx mice, reduces muscle membrane damage, and ameliorates the histopathological signs of muscular dystrophy. [7] MG-132 treatment significantly reduces immobilization-induced skeletal muscle atrophy in mice, by downregulating the muscle-specific ubiquitin ligases atrogin-1/MAFbx and MuRF-1 mRNA. [8]

Protocol

Kinase Assay:

[1]

- Collapse

Measurement of inhibitory activities of MG-132 against 20S proteasome:

The reaction mixture for the 20S proteasome inhibitory assay contains 0.1 M Tris-acetate, pH 7.0, 20S proteasome, MG-132, and 25 μM substrate dissolved in dimethyl sulfoxide in a final volume of 1 mL. After incuba tion at 37 °C for 15 minutes, the reaction is stopped by the addition of 0.1 mL of 10% SDS and 0.9 mL of 0.1M Tris acetate, pH 9.0. The fluorescence of the reaction products is measured. To determine the IC50 against 20S proteasome, various concentrations of MG-132 are included in the assay mixture.
Cell Research:

[3]

- Collapse
  • Cell lines: KIM-2, HC11, and ES
  • Concentrations: Dissolved in DMSO, final concentrations ~25 μM
  • Incubation Time: 24 and 48 hours
  • Method:

    Cells are exposed to various concentrations of MG-132 for 24, and 48 hours. Supernatant and monolayer cells are harvested by centrifugation and fixed in 70% ethanol in PBS for staining with acridine orange. Equal volumes of cells and acridine orange (5 mg/mL in PBS) are mixed on a microscope slide and examined by fluorescence microscopy. For annexin V analysis, cells are harvested by centrifugation and stained with annexin V and propidium iodide. For cell cycle analysis, cells are rehydrated in PBS at room temperature for 10 minutes, followed by staining with propidium iodide (5 mg/mL). All samples are analyzed using a Coulter Epics XL flow cytometer.


    (Only for Reference)
Animal Research:

[7]

- Collapse
  • Animal Models: Male mdx (C57BL/10ScSn DMD mdx) mice
  • Dosages: ~10 μg/kg/day
  • Administration: Injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 90 mg/mL (189.22 mM)
Water Insoluble
Ethanol ''25 mg/mL
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+20% propylene glycol+ddH2O
For best results, use promptly after mixing.
2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 475.62
Formula

C26H41N3O5

CAS No. 1211877-36-9
Storage powder
in solvent
Synonyms N/A
Smiles CC(C)CC(NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)OCC1=CC=CC=C1)C=O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I want to know whether it contains EDTA or other chelating agent in this product(S2619)?

  • Answer:

    Our S2619 MG-132 doesn't contain EDTA or other chelating agent.

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

Related Proteasome Products

Tags: buy MG-132 | MG-132 supplier | purchase MG-132 | MG-132 cost | MG-132 manufacturer | order MG-132 | MG-132 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID